Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Oct 23

PMID 39440958

Authors

Clare Meernik

Frances Wang

Yadurshini Raveendran

Michelle F Green

Devon K Check

Hayden B Bosworth

Linda M Sutton

John H Strickler

Tomi F Akinyemiju

Affiliations

Soon will be listed here.

Abstract

Non-Hispanic Black patients diagnosed with prostate cancer between 2014 and 2019 and treated at a comprehensive cancer center were less likely to use tumor-specific genomic testing compared with non-Hispanic White patients. Disparities in the use of precision oncology technologies should be monitored and addressed to ensure equitable cancer care.

References

Blumenthal G, Mansfield E, Pazdur R . Next-Generation Sequencing in Oncology in the Era of Precision Medicine. JAMA Oncol. 2015; 2(1):13-4. DOI: 10.1001/jamaoncol.2015.4503. View

Lynch J, Berse B, Rabb M, Mosquin P, Chew R, West S . Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013. BMC Cancer. 2018; 18(1):306. PMC: 5859516. DOI: 10.1186/s12885-018-4190-3. View

DeSantis C, Siegel R, Sauer A, Miller K, Fedewa S, Alcaraz K . Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016; 66(4):290-308. DOI: 10.3322/caac.21340. View

Reid S, Cadiz S, Pal T . Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer. Curr Breast Cancer Rep. 2021; 12(3):125-131. PMC: 7885902. DOI: 10.1007/s12609-020-00364-1. View

Palazzo L, Sheehan D, Tramontano A, Kong C . Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2019; 28(5):926-934. PMC: 6500471. DOI: 10.1158/1055-9965.EPI-18-0917. View

Yu M, Tatalovich Z, Gibson J, Cronin K . Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control. 2013; 25(1):81-92. DOI: 10.1007/s10552-013-0310-1. View

Wong W, Wu N, Gupta R, Mansfield A . Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices. Clin Lung Cancer. 2020; 22(3):e470-e480. DOI: 10.1016/j.cllc.2020.06.019. View

Giaquinto A, Miller K, Tossas K, Winn R, Jemal A, Siegel R . Cancer statistics for African American/Black People 2022. CA Cancer J Clin. 2022; 72(3):202-229. DOI: 10.3322/caac.21718. View

Gutierrez M, Choi K, Lanman R, Licitra E, Skrzypczak S, Pe Benito R . Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. Clin Lung Cancer. 2017; 18(6):651-659. DOI: 10.1016/j.cllc.2017.04.004. View

10.

Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B . Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. JAMA Netw Open. 2024; 7(7):e2423186. PMC: 11258596. DOI: 10.1001/jamanetworkopen.2024.23186. View

11.

D Avo Luis A, Seo M . Has the development of cancer biomarkers to guide treatment improved health outcomes?. Eur J Health Econ. 2021; 22(5):789-810. PMC: 8214594. DOI: 10.1007/s10198-021-01290-4. View

12.

OKeefe E, Meltzer J, Bethea T . Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010. Front Public Health. 2015; 3:51. PMC: 4398881. DOI: 10.3389/fpubh.2015.00051. View

13.

Green M, Bell J, Hubbard C, McCall S, McKinney M, Riedel J . Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience. JCO Precis Oncol. 2021; 5. PMC: 8457820. DOI: 10.1200/PO.21.00030. View

14.

Sheinson D, Wong W, Flores C, Ogale S, Gross C . Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing. JCO Oncol Pract. 2021; 17(11):e1774-e1784. PMC: 8600504. DOI: 10.1200/OP.20.01023. View

15.

Gibbs S, Peneva D, Cuyun Carter G, Palomares M, Thakkar S, Hall D . Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer. JCO Precis Oncol. 2023; 7:e2200715. PMC: 10309568. DOI: 10.1200/PO.22.00715. View

16.

Green A, Tabatabai S, Aghajanian C, Landgren O, Riely G, Sabbatini P . Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer. JAMA Oncol. 2022; 8(12):1786-1792. PMC: 9614676. DOI: 10.1001/jamaoncol.2022.5020. View

17.

Kehl K, Lathan C, Johnson B, Schrag D . Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer. J Natl Cancer Inst. 2018; 111(4):431-434. PMC: 6449167. DOI: 10.1093/jnci/djy202. View

18.

Bruno D, Hess L, Li X, Su E, Patel M . Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States. JCO Precis Oncol. 2022; 6:e2100427. DOI: 10.1200/PO.21.00427. View

19.

Al-Ahmadi A, Ardeshir-Larijani F, Fu P, Cao S, Lipka M, Dowlati A . Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. Clin Lung Cancer. 2021; 22(1):16-22.e1. DOI: 10.1016/j.cllc.2020.08.004. View

20.

Denny J, Rutter J, Goldstein D, Philippakis A, Smoller J, Jenkins G . The "All of Us" Research Program. N Engl J Med. 2019; 381(7):668-676. PMC: 8291101. DOI: 10.1056/NEJMsr1809937. View